Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity.

ABSTRACT:

Introduction

Immunogenicity, the unwanted immune response triggered by therapeutic antibodies, poses significant challenges in biotherapeutic development. This response can lead to the production of anti-drug antibodies, potentially compromising the efficacy and safety of treatments. The internalization of therapeutic antibodies into dendritic cells (DCs) is a critical factor influencing immunogenicity. Using monoclonal antibodies, with differences in non-specific cellular uptake, as tools to explore the impact on the overall risk of immunogenicity, this study explores how internalization influences peptide presentation and subsequently T cell activation.

Materials and methods

To investigate the impact of antibody internalization on immunogenicity, untargeted toolantibodies

SUBMITTER: Siegel M 

PROVIDER: S-EPMC11387504 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature